Aurinia Pharmaceuticals ( (AUPH) ) has released its Q3 earnings. Here is a breakdown of the information Aurinia Pharmaceuticals presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing therapies for autoimmune diseases, notably introducing LUPKYNIS, the first FDA-approved oral therapy for lupus nephritis. In its latest earnings report, Aurinia Pharmaceuticals reported a significant increase in net income and product sales for the third quarter of 2025, driven by increased market penetration of LUPKYNIS. The company achieved net product sales of $70.6 million for the quarter, representing a 27% increase compared to the same period in 2024. Operating expenses decreased due to strategic restructuring efforts, leading to a substantial rise in income from operations. Aurinia’s cash position remains strong, with $351.8 million in cash, cash equivalents, and investments as of September 30, 2025, despite significant share repurchases. Looking forward, Aurinia’s management remains optimistic about continued growth and expansion in the autoimmune disease market, supported by ongoing development of new therapies.